A. Facchi, G.D. Kotzalidis, P. Pancheri - Vol. 7, Giugno 2001, num.2
Testo Immagini Bibliografia Summary Riassunto Indice
L’importanza del blocco dei recettori
dopaminergici D3 e D4 nel trattamento della schizofrenia
The relevance of dopamine D3 and D4 receptor blockade for the treatment
of schizophrenia
1 Laborit H, Huguenard P, Alluaume R. Un nouveau stabilisateur végétatif, le 4560 RP. Presse Médicale 1952;60:206-8.
2 Delay J, Deniker P, Harl J-M. Utilisation en thérapeutique psychiatrique d’une phénothiazine d’action centrale élective (4560 RP). Ann Médico-Psychologiques 1952;110:112-7.
3 Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytryptamine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140-4.
4 Randrup A, Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacology 1965;11:300-10.
5 van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Intern Pharmacod Thér (Ghent) 1966;160:492-4.
6 Kebabian JW. Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenyl cyclase. Life Science 1978;23:479-83.
7 Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:93-6.
8 Stoof JC, Kebabian JW. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 1981;294:366-8.
9 Seeman P. Brain dopamine receptors. Pharmacol Rev 1980;32:230-313.
10 Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146-51.
11 Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-4.
12 Sunahara RK, Guan HC, O’Dowd BF, Seeman P, Laurier LG, Ng G, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991;350:614-9.
13 Nguyen T, Bard J, Jin H, Taruscio D, Ward DC, Kennedy JL, et al. Human dopamine D5 receptor pseudogenes. Gene 1991;109:211-8.
14 Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
15 Zivkovic B, Guidotti A, Revuelta A, Costa E. Effects of thioridazine and other antipsychotics on the kinetic state of tyrosine hydroxylase and on the turn over rate of dopamine in striatum and nucleus accumbens. J Pharmacol Exp Ther 1975;194:37-46.
16 Scatton B, Bischoff S, Dedek J, Korf J. Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenyl cyclase activity. Eur J Pharmacol 1977;44:287-92.
17 Csernansky JG, Wrona CT, Bardgett ME, Early TS, Newcomer JW. Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics. Psychopharmacology (Berlin), 1993;110:145-51.
18 Delcker A, Schoon ML, Oczkowski B, Gaertner HJ. Amisulpride versus haloperidol in treatment of schizophrenic patients-Results of a double-blind study. Pharmacopsychiatry 1990;23:125-30.
19 Costall B, Olley JE. Cholinergic- and neuroleptic-induced catalepsy: Modification by lesions in the caudate-putamen. Neuropharmacology 1990;10:297-306.
20 Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. Neurochemical characteristics of amisulpride, an atipical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Exp Ther 1997;280:83-97.
21 Nielsen EB, Andersen PH. Dopamine receptor occupancy in vivo: Behavioral correlates using NNC-112, NNc-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur J Pharmacol 1992;219:35-44.
22 Schotte A, Janssen PF, Megens AA, Leysen JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 1993;631:191-202.
23 Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA. Brain Res 1991;564:203-19.
24 Sokoloff P, Giros B, Martres MP, Andrieux M, Besancon R, Pilon C, et al. Localization and function of D3 dopamine receptor. Arzneimittelforschung 1992;42:224-30.
25 Landwehrmeyer B, Mengod G, Palacios JM. Dopamine D3 m RNA and binding sites in human brain. Molecular Brain Res 1993;18:187-92.
26 Perrault GH, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997;280:73-82.
27 Cummings JL. D-3 receptor agonist: combined action neurologic and neuropsychiatric agents. J Neurol Sci 1999;163:2-3.
28 Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, et al. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997;12:S29-S36.
29 Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999;156:610-6.
30 Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, et al. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 1995;275:1239-46.
31 Levant B, Vansell NR. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology 1997;17:67-71.
32 Bennett JP Jr, Piercey MF. Pramipexole – a new dopamine agonist for the treatment of Parkinson’s disease. J Neurol Sci 1999;163:25-31.
33 Wilner P, Lappas S, Cheeta S, Muskat R. Reversal of stress-induced anhedonia by dopamine agonist, pramipexole. Psychopharmacology (Berlin) 1994;115:454-62.
34 Maj J, Rogoz Z, Skuza G, Kolodziejczyk K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 1997;104:525-33.
35 Lynch MR. Selective effects on prefrontal cortex serotonin by dopamine D3 receptor agonism: interaction with low-dose haloperidol. Progr Neuropsychopharmacol Biol Psychiatry 1997;21:1141-53.
36 Hashimoto T, Kitamura N, Kajimoto Y, Shiraj Y, Shirakawa O, Mita T, et al. Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 1993;112:S35-S39.
37 Abi-Saab WM, Bubser M, Roth RH, Deutch AY. 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 1999;20:92-6.
38 Akbarian S, Huntsman MM, Kim JJ, Tafazzoli A, Potkin SG, Bunney WE Jr, et al. GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cerebral Cortex 1995;5:550-60.
39 Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995;52:258-66; discussion 267-78.
40 Benes FM. Model generation and testing to probe neural circuitry in the cingulate cortex of postmortem schizophrenic brain. Schizophr Bull 1998;24:219-30.
41 Benes FM. The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. J Psychiatr Res 1997;31:257-75.
42 Benes FM, Wickramasinghe R, Vincent SL, Khan Y, Todtenkopf M. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res 1997;755:121-9.
43 Benes FM, Vincent SL, Alsterberg G, Bird ED, San Giovanni JP. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 1992;12:924-9.
44 Todtenkopf MS, Benes FM. Distribution of glutamate decarboxylase65 immunoreactive puncta on pyramidal and nonpyramidal neurons in hippocampus of schizophrenic brain. Synapse 1998;29:323-32.
45 Benes FM, Todtenkopf MS, Taylor JB. Differential distribution of tyrosine hydroxylase fibers on small and large neurons in layer II of anterior cingulate cortex of schizophrenic brain. Synapse 1997;25:80-92.
46 Benes FM, Vincent SL, Marie A, Khan Y. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 1996;75:1021-31.
47 Benes FM, Khan Y, Vincent SL, Wickramasinghe R. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse 1996;22:338-49.
48 Benes FM. Altered glutamatergic and GABAergic mechanisms in the cingulate cortex of the schizophrenic brain. Arch Gen Psychiatry 1995;52:1015-8; discussion 1019-24.
49 Benes FM, Vincent SL, Molloy R. Dopamine-immunoreactive axon varicosities form nonrandom contacts with GABA-immunoreactive neurons of rat medial prefrontal cortex. Synapse 1993;15:285-95.
50 Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Rivière M-E, Papillion-Downey C. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry 1999;156:419-25.
51 Sharma A, Kramer ML, Wick PF, Liu D, Chari S, Shim S, et al. D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illness such as schizophrenia. Mol Psychiatry 1999;4:235-46.
52 Kulagowski JJ, Broughton HB, Curtis NR, Mawer IM, Ridgill MP, Baker R, et al. 3-[[4-(4-Chlorophenyl)piperazin-1-yl]-methyl]-1H-pyrrolo[2,3-b]pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J Med Chem 1996;39:1941-2.
53 Patel S, Patel S, Marwood R, Fletcher R, Kulagowski J, Ragan CI, et al. L-745,870 3-[[4-(4-Chlorophenyl)piperazin-1-yl]-methyl]-1H-pyrrolo[2,3-b]pyridine: a high affinity and selective dopamine D4 receptor antagonist. Br J Pharmacol 1996;119:30P.
54 Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, et al. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J Pharmacol Exp Ther 1997;283:636-47.
55 Rowley M, Broughton HB, Colins I, Baker R, Emms F, Marwood R, et al. 4-4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isossazolo: A potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem 1996;39:1943-5.
56 Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Bruinvels AT, Geisse S. The agonist activities of the putative antipsychotic agents, L-745-870 and U-101958 in HEK 293 cells expressing the human dopamine D4.4 receptor. Br J Pharmcol 1998;124:889-96.
57 Kramer MS, Last B, Getson A, Reines SA. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry 1997;54:567-72.
58 Kelly PH, Seviour PW, Iversen SD. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Br Res 1975;94:507-22.
59 Pijnenburg AJJ, Honig WMM, Van Rossum JM. Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat. Psychopharmacology (Berlin) 1975;41:87-95.
60 Costall B, Naylor RJ. On the mode of action of apomorphine. Eur J Pharmacol 1973:350-61.
61 Reynolds GP. The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs 1996;51:7-11.
62 Matsumoto M, Hidaka K, Tada S, Tasaki Y, Yamaguchi T. Full lenght cDNA cloning and distribution of dopamine D4 receptor. Brain Res Mol Brain Res 1995;29:157-62.
63 Roberts GW. Schizophrenia: a neuropathological perspective. Br J Psychiatry 1991;158:8-17.
64 Bristow LJ, Collins N, Cook GP, Curtis N, Freedman SB, Kulagowski JJ, et al. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther 1997;283:1256-63.
65 Camacho Ochoa M, Walker EL, Evans DL, Piercey MF. Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist. Neurosci Lett 1995;196:97-100.
66 Sokoloff PM, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146-51.
67 Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999;20:60-80.
68 Rayevskij KS. Functional role and pharmacological regulation of the dopaminergic system of the brain. Vestnik Rossiji Akademii Meditsinskikh Nauk (Moskva) 1998;8:19-24.
69 Svensson K, Carlsson A, Huff RM, Kling-Petersen T, Waters N. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol 1994;263:235-43.
70 Waters N, Lagerkvist S, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A. The dopamine D3 receptor: A postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm 1993;94:11-9.
71 Andreasen NC, Arndt S, Swayze V II, Cizadlo T, Flaum M, O’Leary D, et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994;266:294-8.
72 Deutch AY, Bubser M, Young CD. Psychostimulant-induced Fos protein expression in the thalamic paraventricular nucleus. J Neurosci 1998;18:10680-7.
73 Danos P, Baumann B, Bernstein HG, Franz M, Stauch R, Northoff G, et al. Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res 1998;82:1-10.
74 Joyce JN, Gurevich EV. D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Ann N Y Acad Sci 1999;877:595-613.
75 Meador-Woodruff JH, Damask SP, Wang J, Haroutounian V, Davis KL, Watson SJ. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology, 1996; 15: 17-29.
76 Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. Mesolimbic dopamine D3 receptor and use of antipsychotic in patients with schizofrenia. A post-mortem study. Arch Gen Psychiatry 1997;54:225-32.
77 Damask SP, Bovenkerk KA, de la Pena G, Hoversten KM, Peters DB, Valentine AM, et al. Differential effects of clozapine and haloperidol on dopamine receptor mRMA expression in rat striatum and cortex. Brain Res Mol Brain Res 1996;41:241-9.
78 Csernansky JG, Murphy GM, Faustman WO. Limbic/mesolimbic connections and the pathogenesis of schizophrenia. Biol Psychiatry 1991;30:383-400.
79 Almaric M, Koob GF. Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system. Prog Brain Res 1993;99:209-26.
80 Egan MF, Hurd Y, Hyde TM, Weinberger DR, Wyatt RJ, Kleinman JE. Alterations in mRNA levels of D2 receptors and neuropeptides in nigrostriatal neurons of rats with neuroleptic induces dyskinesias. Synapse 1994;18:178-89.
81 Weinberger DR. D1 e D2 receptor modulation in rat striatum and nucleus accumbens after chronic haloperidol treatment. Brain Res 1992;575:47-56.
82 Schoots O, Seeman P, Guan HC, Paterson AD, Van Tol HH. Long-term haloperidol elevates dopamine D4 receptor by 2-fold in rats. Eur J Pharmacol 1995;289:67-72.
83 Murray AM, Ryoo H, Gurevich E, Joyce JN. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A 1994;91:11271-5.
84 Seeman P, Guan H-C, Van Tol HHM, Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441-45.
85 Mackay AVP, Iversen L, Rossor M, Spokes E, Bird E, Arregui A, et al. Increased brain dopamine and dopamine recptors in schizophrenia. Arch Gen Psychiatry 1982; 39: 991-991.
86 Reynolds GP, Mason SL. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. Eur J Pharmacol 1995;281:R5-R6.
87 Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995;15:2186-91.
88 Seeman P, Guan HC, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441-5.
89 Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY. Dopamine D4 receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride. J Neurochemistry 1995;64:1413.
90 Reynolds GP, Mason SL. Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochemistry 1994;63:1576-7.
91 Lahti RA, Roberts RC, Cochrane EV, Primus RJ, Gallager DW, Tamminga CA. [3H]NGD-94-1 binding in human postmortem brain of normals and schizophrenics off-, or on-antipsychotic drugs at death. Schizophr Res 1997;24:35-45.
92 Stefanis NC, Bresnick JN, Kerwin RW, Schofield WN, McAllister G. Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. Brain Res Mol Brain Res 1998;53:112-9.
93 O’Malley KL, Harmon S, Tang L, Todd RD. The rat dopamine D4 receptor: sequence, gene structure, and demostration of expression in the cardiovascolary system. New Biology 1992;4:137-46.
94 Mulcrone J, Kerwin RW. No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics. Neurosci Lett 1996;219:163-6.
95 Roberts DA, Balderson D, Pickering Brown SM, Deakin JF, Owen F. The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls. Schizophr Res 1996;20:171-4.
96 Martin KAC. Form single cells to simple circuits in the cerebral cortex. Quart J Exp Physiology 1988;73:637-702.
97 Benes FM, Todenkopf MS, Taylor JB. Differential distribution of tyrosine hydroxylase fibers on small and large neurons in layers II of anterior cingulate cortex of schizophrenic brain. Synapse 1991;25:80-92.
98 Sokoloff P, Martres M-P, Giros B, Boutheneth M-L, Schewartz J-C. The third dopamine (D3) as a novel target for antipsychotics. Biochem Pharmacol 1992;43:659-66.
99 Zenner M-T, Nobile M, Henninges R, Smeraldi E, Civelli O, Hartman DS, et al. Expression and characterization of dopamine D4R variant associated with delusional disorder. FEBS Lett 1998;422:146-50.
100 Castellanos FX, Lau E, Tayebi N, Lee P, Long RE, Giedd JN, et al. Lack of an association between a dopamine-4 receptor polymorphism and attention-deficit/hyperactivity disorder: genetic and brain morphometric analyses. Mol Psychiatry 1998;3:431-4.
101 Crocq M-A, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, et al. Association between schizophrenia and omozygosity at the dopamine D3 receptor gene. J Med Genet 1992;29:858-60.
102 Krebs M-O, Sautel F, Bourdel M-C, Sokoloff P, Schwartz J-C, Olié J-P, et al. Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Mol Psychiatry 1998;3:337-41.
103 Ebstein RP, Macciardi F, Heresco-Levi U, Serretti A, Blaine D, Verga M, et al. Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Hum Heredity 1997;47:6-16.
104 Gelernter J, Kranzler H, Lacobelle J. Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), m opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF)). Genomics 1998;52:289-97.
105 Steen VM, Løvlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139-45.
106 Maziade M, Martinez M, Rodrigue C, Gauthier B, Tremblay G, Fournier C, et al. Childhood/early adolescence-onset and adult-onset schizophrenia. Br J Psychiatry 1997;170:27-30.
107 Karayiorgou M, Gogos JA. A turning point in schizophrenia genetics. Neuron 1997;19:967-79. Dissecting the genetic complexity of schizophrenia. Mol Psychiatry 1997;2:211-23.
108 Shaikh S, Ball D, Craddock N, Castle D, Hunt N, Mant R, et al. The dopamine D3 receptor gene: no association with bipolar affective disorder. J Med Genet 1993;30:308-9.
109 Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4:247-53.
110 Özdemir BV, Masellis M, Basile VS, Kalow W, Meltzer HY, Lieberman JA, et al. Variability in response to clozapine: potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene. CNS Spectrums 1999;4:30-56.
111 Hwu HG, Hong CJ, Lee YL, Lee PC, Lee SF. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry 1998;44:483-7.
112 Shaikh S, Collier DA, Sham PC, Ball D, Aitchison K, Vallada H, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996;97:714-9.
113 Malhotra AK, Goldman D, Buchanan RW, Rooney W, Clifton A, Kosmidis MH, et al. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 1998;3:72-5.
114 Petronis A. The regulation of D2 dopamine receptor gene expression: epigenetic factors should not be forgotten. Mol Psychiatry 1999,4:212-3.
115 Hong C-H, Chiu H-J, Chang Y-S, Sim C-B. Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in chinese familial schizophrenic patients. Biol Psychiatry 1998;43:432-5.
116 Paterson AD, Ying DJ, Petronis A, Schoots O, Lieberman JA, Van Tol HH, et al. A PstI restriction fragment length polymorphism in the 5’ untranslated region of DRD4 is not associated with schizophrenia. Psychiatr Genet 1996;6:191-3.
117 Williams J, Spurlock G, Holmans P, Mant R, Murphy K, Jones L, et al. A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia. Mol Psychiatry 1998;3:141-9.
118 Lahti AC, Weiler M, Carlsson A, Tamminga CA. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J Neural Transm 1998;105:719-34.
119 Chabannes JP, Pelissolo A, Farah S, Gerard D. évaluation de l’efficacité et tolérance de l’amisulpride dans le traitement des psychoses schizophréniques. Encephale 1998;24:386-92.
120 Loô H, Poirier-Littre MF, Théron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22.
121 Kasper S, Barnas C, Heiden A, Volz HP, Laakmann G, Zeit H, et al. Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur Neuropsychopharmacol 1997;7:65-70.
122 Satoh K, Someya T, Shibasaki M. Nemonapride for the treatment of schizophrenia [letter]. Am J Psychiatry 1997;154:292.
123 Satoh K, Someya T, Shibasaki M. Effects of nemonapride on positive and negative symptoms of schizophrenia. Int Clin Psychopharmacol 1996;11:279-81.
124 Heuillet E, Petitet F, Mignani S, Malleron JL, Lavayre J, Néliat G, et al. The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor. Eur J Pharmacol 1996;314:229-33.